RESTASIS® & Artificial Tears

The therapeutic benefits of using RESTASIS® Ophthalmic Emulsion will occur with continued use by patients over time. Artificial tears, such as REFRESH® Brand Lubricant Eye Drops, can be used concomitantly to alleviate Dry Eye symptoms.

Within a month, patients may start producing more of their own tears. Patients will know they're getting better when they start feeling less need to use artificial tears. Over the first 6 months of treatment with RESTASIS® Ophthalmic Emulsion, their use of artificial tears is likely to decrease. Individual results may vary.

Your Patients Can Use REFRESH® OPTIVE™ Lubricant Eye Drops Concomitantly With RESTASIS®

REFRESH® OPTIVE™ Lubricant Eye Drops are the only artificial tears designed to work in two ways for long-lasting relief of Dry Eye symptoms1,2

  • Lubricates - REFRESH® OPTIVE™ acts on the tear film to provide a lubricating and hydrating protective shield to the ocular surface
  • Protects - REFRESH® OPTIVE™ hydrates and protects the ocular surface cells that can become damanged due to Dry Eye

REFRESH® OPTIVE™ Lubricant Eye Drops contain carboxymethylcellulose for hydration and lubrication, glycerin for deep hydration of the corneal epithelial cells, and PURITE® preservative for gentle, antimicrobial protection.

For more information on REFRESH® OPTIVE™ and the entire REFRESH® family of eye drops, please visit www.refreshbrand.com.

Indication and Usage: RESTASIS® Ophthalmic Emulsion is indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca. Increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctal plugs.

Important Safety Information:

Contraindications: RESTASIS® is contraindicated in patients with active ocular infections and in patients with known or suspected hypersensitivity to any of the ingredients in the formulation.

Warning: RESTASIS® Ophthalmic Emulsion has not been studied in patients with a history of herpes keratitis.

Precautions: RESTASIS® should not be administered while wearing contact lenses. If contact lenses are worn, they should be removed prior to the administration of the emulsion.

Adverse Reactions: The most common adverse event was ocular burning (upon instillation) – 17%. Other events reported in 1% to 5% of patients included conjunctival hyperemia, discharge, epiphora, eye pain, foreign body sensation, pruritus, stinging, and visual disturbance (most often blurring).

Please see full prescribing information for RESTASIS® Ophthalmic Emulsion.

References
  1. Clinical Trial #AG9689-001. Data on file, Allergan, Inc.
  2. Data on file, Allergan, Inc.